BioCorRx Inc. (OTC: BICX), a developer of treatment support programs for substance use disorders, announced the appointment of Richard J. Baum to its Strategic Advisory Board. Baum is a former Acting Director of the White House Office of National Drug Control Policy (ONDCP) and former Executive Director of the President's Commission on Combating Drug Addiction and the Opioid Crisis. His nearly three decades of experience in national drug policy, addiction, public health, law enforcement, and justice policy position him to guide BioCorRx as it advances its treatment and pharmaceutical strategies.
During 28 years at ONDCP, Baum served across six presidential administrations and helped shape federal responses to evolving drug threats, including the opioid crisis. His expertise spans treatment and recovery policy, prevention, public safety, interagency coordination, and collaboration with state and local partners. This background is expected to support BioCorRx's engagement with treatment and recovery organizations, public health agencies, healthcare systems, justice-system partners, and policymakers.
BioCorRx's portfolio includes LUCEMYRA® (lofexidine), an FDA-approved non-opioid medication indicated for the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults, and BICX104, an investigational biodegradable naltrexone implant technology. The company also operates Beat Addiction Recovery, a substance use disorder recovery program that typically includes proprietary Cognitive Behavioral Therapy modules along with peer support via mobile app and medication prescribed by an independent treating physician.
Lourdes Felix, Chief Executive Officer of BioCorRx Inc., said, "Rich has spent his career at the intersection of drug policy, public health, treatment, and public safety, and we are honored to welcome him to BioCorRx. His deep understanding of how policy translates into real-world treatment access will be invaluable as we work to expand awareness of evidence-based approaches to addiction treatment and thoughtfully position our programs within the broader continuum of care."
Baum commented, "I am pleased to join BioCorRx as a strategic advisor at a time when the country continues to face significant challenges related to opioid use, addiction treatment, and recovery. BioCorRx is working across several important points in the treatment continuum, including managing opioid withdrawal symptoms with LUCEMYRA. In an era of increasingly dangerous polysubstance use, particularly involving illicit fentanyl and methamphetamine, I am also encouraged by the Company's research evaluating BICX104, an investigational long-duration naltrexone implantable pellet, as a potential treatment for methamphetamine use disorder. I look forward to helping BioCorRx position these approaches within a comprehensive, evidence-based system of care that expands treatment access, supports retention, and improves long-term recovery."
The appointment comes as the U.S. continues to grapple with high rates of opioid use disorder and methamphetamine use. According to the 2025 National Survey on Drug Use and Health, an estimated 4.0 million people aged 12 or older had an opioid use disorder in the past year, while approximately 2.7 million reported using methamphetamine in the past year and over 15 million have used it at least once in their lifetime. BioCorRx is conducting an ongoing NIDA-supported clinical study of BICX104, alone and in combination with bupropion, as a potential treatment for methamphetamine use disorder.
Baum is an Adjunct Professor at Georgetown University's McCourt School of Public Policy and author of Inside America's Opioid Crisis: 12 Hard Lessons for Today's Drug War. He also serves on the United Against Fentanyl Board of Directors. For more information about BioCorRx, visit www.BioCorRx.com. For details on UnCraveRx®, visit www.uncraverx.com.
